港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目维持今年收入增长最多17%预期-To The Moon - Tiger Brokers Online Investing Community

Like
Comment
Favorite

港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目维持今年收入增长最多17%预期

智通财经06-01

【港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目维持今年收入增长最多17%预期】智通财经APP获悉，药明生物(02269.HK)涨超4%，截至发稿，涨4.26%，报34.76港元，成交额13.23亿港元。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2640291939?lang=en_US&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-06-01 15:31","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2640291939","market":"hk","top_or_hot":-1,"title":"港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期】</b>智通财经APP获悉，药明生物(02269.HK)涨超4%，截至发稿，涨4.26%，报34.76港元，成交额13.23亿港元。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-06-01 15:31 北京时间&nbsp;&nbsp;&nbsp;<a href=https://www.zhitongcaijing.com/immediately.html?type=ganggu><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>【港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期】智通财经APP获悉，药明生物(02269.HK)涨超4%，截至发稿，涨4.26%，报34.76港元，成交额13.23亿港元。</p>\n\n<a href=\"https://www.zhitongcaijing.com/immediately.html?type=ganggu\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","article_id":"2640291939","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2640291939","pubTimestamp":1780299110,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期】智通财经APP获悉，药明生物(02269.HK)涨超4%，截至发稿，涨4.26%，报34","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{},"translate_title":"Changes in Hong Kong stocks | WuXi Biologics (02269.HK) rose by more than 4%. 69 new comprehensive projects were signed in the first four months, maintaining the forecast of revenue growth of up to 17% this year","themeId":"dbd4a422ef4d87750cf8d9255f6a482f","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"【港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期】智通财经APP获悉，药明生物(02269.HK)涨超4%，截至发稿，涨4.26%，报34.76港元，成交额13.23亿港元。","kind":"live","is_publish_news":false,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"isCrawlerRequest":true}

港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目 维持今年收入增长最多17%预期

Comment

Most Discussed

7x24

港股异动 | 药明生物(02269.HK)涨超4% 前四月新签69个综合项目维持今年收入增长最多17%预期